Please login to the form below

Not currently logged in
Email:
Password:

More Eloxatin settlements for sanofi-aventis

S-A has announced a further three settlements with companies making generic versions of cancer drug, Eloxatin, following three last week

Sanofi-aventis (S-A) has announced a further three settlements with companies making generic versions of colon cancer drug, Eloxatin (oxaliplatin), following three announced last week.

Mayne/Hospira, MN/Par and Actavis have all settled outstanding litigation regarding certain formulations of Eloxatin, currently under licence by S-A and Debiopharm.

This follows the news announced on April 1 that drugs manufacturers Teva Pharmaceuticals, Fresenius Kabi and Sandoz had all settled similar litigation with S-A.

As with these previous agreements, the settlements involving Mayne/Hospira, MN/Par and Actavis mean the companies will have to cease selling their generic Eloxatin products in the US between June 30, 2010 and August 9, 2012.

Sales can then resume under a licence, a year before the expiry of the patents at issue.

Financial details of the settlements remain undisclosed, though Mayne/Hospira said in a statement the settlement "will not affect" the company's financial guidance for 2010.

All settlement details are "subject to contingencies".

There is still further outstanding litigation involving generic Eloxatin, with Sun Pharmaceuticals currently marketing their own version of the drug. However, the US District Court for the District of New Jersey has found a proposed settlement agreement between S-A and Sun to be "enforceable".

If settled, it is the position of S-A that Sun cease marketing their product on the same date as the other generic manufacturers involved. The case is subject to appeal.

6th April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics